Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial
- PMID: 27155210
- DOI: 10.1016/j.ijid.2016.04.024
Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial
Abstract
Objective: The majority of patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) have low serum procalcitonin (PCT) values. The aim of this study was to determine whether these patients may benefit from antibiotic treatment.
Methods: A total of 457 patients with AECOPD were screened; 194 patients with AECOPD and PCT <0.1 ng/ml were assigned randomly to an antibiotic group or a control group. In the per-protocol (PP) population, the antibiotic group subjects were required to have used antibiotics for at least 3 days, and the control group subjects were required not to have used antibiotics within the 10 days after admission. The intention-to-treat (ITT) population was defined as the patients who were randomized. The primary outcome was the treatment success rate on day 10 after admission. Secondary outcomes were symptoms assessed on a visual analog scale (VAS), length of hospitalization, mortality, exacerbation rate, and re-hospitalization within 30 days of follow-up (study registered at chictr.org.cn: ChiCTR-TRC-14004726).
Results: 95 patients in the antibiotic group and 96 patients in the control group completed the study. In the ITT population, the overall treatment success rate in the control group (95.8%) was similar to that in the antibiotic group (93.7%), with no significant difference (p=0.732). Five patients in the antibiotic group died, either in hospital or within 30 days of discharge. In the control group, two died within 30 days of discharge. Antibiotic use in the control group was 17.7% (17/96), and age ≥75 years was a predictive risk factor for requiring antibiotic therapy in the control group (odds ratio 4.055, 95% confidence interval 1.297-12.678; p=0.012). According to the PP analysis, the treatment success rate on day 10 after admission was 98.7% (78/79) in the control group and 93.7% (89/95) in the antibiotic group, also with no significant difference (p=0.193). No secondary outcome was significantly different between the two groups.
Conclusion: Antibiotic treatment is no better than placebo in AECOPD with a PCT level <0.1 ng/ml.
Keywords: Acute exacerbation; Antibiotics; Chronic obstructive pulmonary disease; Procalcitonin.
Copyright © 2016 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Procalcitonin-guided use of antibiotic in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: a randomized clinical trial.Clin Microbiol Infect. 2025 May;31(5):785-792. doi: 10.1016/j.cmi.2024.12.004. Epub 2024 Dec 9. Clin Microbiol Infect. 2025. PMID: 39662822 Clinical Trial.
-
Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy.Chest. 2007 Jan;131(1):9-19. doi: 10.1378/chest.06-1500. Chest. 2007. PMID: 17218551 Clinical Trial.
-
Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12-month follow-up.Crit Care. 2014 Sep 5;18(5):471. doi: 10.1186/s13054-014-0471-7. Crit Care. 2014. PMID: 25189222 Free PMC article. Clinical Trial.
-
Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations.Expert Rev Anti Infect Ther. 2011 Jun;9(6):727-35. doi: 10.1586/eri.11.45. Expert Rev Anti Infect Ther. 2011. PMID: 21692680 Review.
-
Potential of serum procalcitonin in predicting bacterial exacerbation and guiding antibiotic administration in severe COPD exacerbations: a systematic review and meta-analysis.Infect Dis (Lond). 2019 Sep;51(9):639-650. doi: 10.1080/23744235.2019.1644456. Epub 2019 Jul 29. Infect Dis (Lond). 2019. PMID: 31355690
Cited by
-
Predictors of Readmission, for Patients with Chronic Obstructive Pulmonary Disease (COPD) - A Systematic Review.Int J Chron Obstruct Pulmon Dis. 2023 Nov 18;18:2581-2617. doi: 10.2147/COPD.S418295. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 38022828 Free PMC article.
-
Characteristics, Management and In-Hospital Clinical Outcomes Among Inpatients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in China: Results from the Phase I Data of ACURE Study.Int J Chron Obstruct Pulmon Dis. 2021 Feb 25;16:451-465. doi: 10.2147/COPD.S281957. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 33658775 Free PMC article. Review.
-
Management of severe acute exacerbations of COPD: an updated narrative review.Multidiscip Respir Med. 2018 Oct 2;13:36. doi: 10.1186/s40248-018-0149-0. eCollection 2018. Multidiscip Respir Med. 2018. PMID: 30302247 Free PMC article. Review.
-
Upper-extremity function prospectively predicts adverse discharge and all-cause COPD readmissions: a pilot study.Int J Chron Obstruct Pulmon Dis. 2018 Dec 18;14:39-49. doi: 10.2147/COPD.S182802. eCollection 2019. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 30587960 Free PMC article.
-
Antibiotics for exacerbations of chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2018 Oct 29;10(10):CD010257. doi: 10.1002/14651858.CD010257.pub2. Cochrane Database Syst Rev. 2018. PMID: 30371937 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous